Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 14/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.59 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353441 | 0.89 | ROCK2 (0.55) | ROCK1ROCK2ATG4BL3MBTL1SMN1; SMN2 | |
| SCHEMBL353440 | 0.89 | ROCK2 (0.55) | ROCK1ROCK2ATG4BL3MBTL1SMN1; SMN2 | |
| SCHEMBL10466253 | 0.88 | ROCK2 (0.55) | ROCK1ROCK2L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL10464664 | 0.85 | L3MBTL1 (0.62) | L3MBTL1SMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL353107 | 0.83 | ROCK1 (0.68) | ROCK1ROCK2ATG4BEPHX2 | |
| SCHEMBL368549 | 0.83 | TSHR (0.52) | ROCK1ROCK2L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL4727779 | 0.82 | MAPT (0.64) | ROCK1ROCK2L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10237515 | 0.80 | ROCK1 (0.67) | ROCK1ROCK2ATG4BEPHX2 | |
| SCHEMBL10465403 | 0.79 | MAPT (0.55) | ROCK1L3MBTL1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10465812 | 0.78 | MAPT (0.66) | ROCK1L3MBTL1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ROCK1 4747/4885ROCK2 4626/4885ATG4B 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.